Kendall Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.43M | Buy |
24,945
+27
| +0.1% | +$5.99K | 1.11% | 20 |
|
|
2025
Q4 | $5.69M | Sell |
24,918
-1,324
| -5% | -$302K | 1.19% | 22 |
|
|
2025
Q3 | $6.08M | Sell |
26,242
-722
| -3% | -$147K | 1.37% | 16 |
|
|
2025
Q2 | $5.01M | Sell |
26,964
-626
| -2% | -$116K | 1.32% | 18 |
|
|
2025
Q1 | $5.78M | Sell |
27,590
-2,557
| -8% | -$497K | 1.7% | 11 |
|
|
2024
Q4 | $5.36M | Sell |
30,147
-1,905
| -6% | -$350K | 1.57% | 13 |
|
|
2024
Q3 | $6.33M | Sell |
32,052
-675
| -2% | -$126K | 1.95% | 8 |
|
|
2024
Q2 | $5.61M | Sell |
32,727
-126
| -0.4% | -$20.9K | 1.87% | 9 |
|
|
2024
Q1 | $5.98M | Sell |
32,853
-615
| -2% | -$106K | 2.06% | 6 |
|
|
2023
Q4 | $5.19M | Buy |
33,468
+1,033
| +3% | +$151K | 2.01% | 6 |
|
|
2023
Q3 | $4.83M | Buy |
32,435
+195
| +0.6% | +$28.6K | 2.14% | 6 |
|
|
2023
Q2 | $4.34M | Buy |
32,240
+731
| +2% | +$107K | 1.9% | 7 |
|
|
2023
Q1 | $5.02M | Buy |
31,509
+347
| +1% | +$53.1K | 2.41% | 5 |
|
|
2022
Q4 | $5.04M | Sell |
31,162
-947
| -3% | -$145K | 2.54% | 5 |
|
|
2022
Q3 | $4.31M | Sell |
32,109
-370
| -1% | -$53.1K | 2.51% | 4 |
|
|
2022
Q2 | $4.97M | Sell |
32,479
-845
| -3% | -$129K | 2.74% | 3 |
|
|
2022
Q1 | $5.4M | Sell |
33,324
-1,815
| -5% | -$264K | 2.61% | 5 |
|
|
2021
Q4 | $4.76M | Sell |
35,139
-796
| -2% | -$94K | 2.26% | 7 |
|
|
2021
Q3 | $3.88M | Sell |
35,935
-930
| -3% | -$106K | 2.1% | 9 |
|
|
2021
Q2 | $4.15M | Sell |
36,865
-635
| -2% | -$71.5K | 2.33% | 7 |
|
|
2021
Q1 | $4.06M | Buy |
37,500
+310
| +0.8% | +$33.2K | 2.51% | 7 |
|
|
2020
Q4 | $3.98M | Sell |
37,190
-335
| -0.9% | -$32.2K | 2.91% | 4 |
|
|
2020
Q3 | $3.29M | Buy |
37,525
+870
| +2% | +$81.9K | 2.86% | 4 |
|
|
2020
Q2 | $3.6M | Buy |
36,655
+3,575
| +11% | +$315K | 3.45% | 2 |
|
|
2020
Q1 | $2.52M | Sell |
33,080
-2,906
| -8% | -$248K | 2.85% | 4 |
|
|
2019
Q4 | $3.19M | Buy |
35,986
+1,022
| +3% | +$84.8K | 2.51% | 4 |
|
|
2019
Q3 | $2.65M | Buy |
34,964
+2,570
| +8% | +$176K | 2.34% | 5 |
|
|
2019
Q2 | $2.36M | Buy |
32,394
+878
| +3% | +$69K | 2.13% | 7 |
|
|
2019
Q1 | $2.54M | Buy |
31,516
+1,345
| +4% | +$110K | 2.41% | 6 |
|
|
2018
Q4 | $2.78M | Sell |
30,171
-483
| -2% | -$42.5K | 2.88% | 3 |
|
|
2018
Q3 | $2.9M | Buy |
30,654
+1,963
| +7% | +$186K | 2.47% | 6 |
|
|
2018
Q2 | $2.66M | Buy |
28,691
+965
| +3% | +$94.2K | 2.35% | 7 |
|
|
2018
Q1 | $2.62M | Sell |
27,726
-85
| -0.3% | -$9.34K | 2.27% | 7 |
|
|
2017
Q4 | $2.69M | Buy |
+27,811
| New | +$2.62M | 2.39% | 7 |
|
Other funds holding ABBV
VCM
VPM
Kendall Capital Management's ABBV Position: Q1 2026 in Review
Kendall Capital Management increased its AbbVie (ABBV) stake by 0.11% in Q1 2026, buying an estimated $5.99K and bringing the position to 24,945 shares worth $5.43M. The position accounts for 1.11% of the portfolio, ranked #20.
Kendall Capital Management first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $6.33M in Q3 2024. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Kendall Capital Management held 24,945 shares of AbbVie worth $5.43M as of Q1 2026.
- Kendall Capital Management bought 27 AbbVie shares in Q1 2026, an estimated $5.99K.
- AbbVie made up 1.11% of Kendall Capital Management's portfolio in Q1 2026, its #20 holding.
- Kendall Capital Management first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Kendall Capital Management's AbbVie position peaked at $6.33M in Q3 2024.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.